Form 4: ImmunityBio Director Exercises Stock Options, Acquires 110,020 Shares

ImmunityBio director Barry J. Simon exercised stock options to acquire 110,020 shares of common stock at a price of $1.9984 per share.

Summary

• Barry J. Simon, a director at ImmunityBio, Inc., exercised stock options on January 22, 2025.
• This transaction resulted in the acquisition of 110,020 shares of common stock at a price of $1.9984 per share.
• Following the transaction, Mr. Simon directly owns 3,233,781 shares of ImmunityBio common stock.
• The options exercised were set to expire on February 16, 2025.
• The options vested monthly over two years from a commencement date of January 16, 2015.

Sentiment

Score: 5

Explanation: The document is a neutral report of a routine stock option exercise. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the biotechnology industry.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule described is typical, with monthly vesting over a two-year period.
• The transaction is similar to those seen at other biotech companies such as Amgen, Gilead, and Regeneron, where executives and directors regularly exercise stock options.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of other shareholders.

Key Dates

Keywords

stock options, insider trading, share acquisition, beneficial ownership, ImmunityBio, IBRX, director